S
Samvel B. Gasparyan
Researcher at AstraZeneca
Publications - 13
Citations - 317
Samvel B. Gasparyan is an academic researcher from AstraZeneca. The author has contributed to research in topics: Medicine & Dapagliflozin. The author has an hindex of 4, co-authored 6 publications receiving 46 citations.
Papers
More filters
Journal ArticleDOI
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mikhail Kosiborod,Mikhail Kosiborod,Russell Esterline,Remo H.M. Furtado,Jan Oscarsson,Samvel B. Gasparyan,Gary G. Koch,Felipe Martinez,Omar Mukhtar,Subodh Verma,Subodh Verma,Vijay K. Chopra,Joan Buenconsejo,Anna Maria Langkilde,Philip Ambery,Fengming Tang,Kensey Gosch,Sheryl L. Windsor,Emily E Akin,Ronaldo V P Soares,Diogo D.F. Moia,Matthew Aboudara,Conrado R. Hoffmann Filho,Audes D. M. Feitosa,Alberto Fonseca,Vishnu Garla,Robert Gordon,Ali Javaheri,Cristiano P Jaeger,Paulo Leães,Michael E. Nassif,Michael Pursley,Fabio Serra Silveira,Weimar Kunz Sebba Barroso,José Roberto Lazcano Soto,Lilia Nigro Maia,Otavio Berwanger +36 more
TL;DR: The DARE-19 trial as discussed by the authors was a randomized, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (i.e., hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease).
Journal ArticleDOI
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Pardeep S. Jhund,Toru Kondo,Jawad H. Butt,Kieran F. Docherty,Brian Claggett,Akshay S. Desai,Muthiah Vaduganathan,Samvel B. Gasparyan,Olof Bengtsson,Dan Lindholm,Magnus Petersson,Anna Maria Langkilde,W. De Boer,David L. DeMets,Adrian F. Hernandez,Silvio E. Inzucchi,Mikhail Kosiborod,Lars Køber,Carolyn S.P. Lam,Felipe Martinez,Marc S. Sabatine,Scott D. Solomon,John J.V. McMurray +22 more
TL;DR: A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction (≤40% and >40%) was pre-specified to examine the effect of treatment on endpoints that neither trial, individually, was powered for and to test the consistency of the effect across the range of ejection fractions as mentioned in this paper .
Journal ArticleDOI
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Mikhail Kosiborod,Mikhail Kosiborod,Otavio Berwanger,Gary G. Koch,Felipe Martinez,Omar Mukhtar,Subodh Verma,Subodh Verma,Vijay K. Chopra,Ali Javaheri,Philip Ambery,Samvel B. Gasparyan,Joan Buenconsejo,C. David Sjöström,Anna Maria Langkilde,Jan Oscarsson,Russell Esterline +16 more
TL;DR: Dapagliflozin, a sodium‐glucose cotransporter‐2 inhibitor, has shown significant cardio‐ and renoprotective benefits in patients with type 2 diabetes, heart failure and chronic kidney disease, and may provide similar organ protection in high‐risk patients with COVID‐19.
Journal ArticleDOI
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.
Pardeep S. Jhund,Piotr Ponikowski,Kieran F. Docherty,Samvel B. Gasparyan,Michael Böhm,Chern-En Chiang,Akshay S. Desai,Jonathon Howlett,Masafumi Kitakaze,Mark C. Petrie,Subodh Verma,Olof Bengtsson,AM Langkilde,Mikaela Sjöstrand,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Mikhail Kosiborod,Felipe Martinez,Marc S. Sabatine,Scott D. Solomon,John J.V. McMurray +21 more
TL;DR: In this paper, the authors assessed the efficacy of heart failure patients with reduced ejection fraction (RFE) and heart failure during the course of their disease and found that patients with RFE experienced multiple hospitalizations for heart failure.
Journal ArticleDOI
Adjusted win ratio with stratification: Calculation methods and interpretation.
TL;DR: It is shown that the win ratio gives an interpretable treatment effect measure with corresponding test to detect treatment effect difference under minimal assumptions.